While TE values were slightly increased in patients that received UDCA, the biomarkers TIMP-4, Endoglin and PTX3 were not significantly altered between CF patients with and without UDCA treatment (Figure S3) and there was no association between the duration of UDCA therapy and liver stiffness and biomarker expression (data not shown). This evidence concerns the gene PTX3 and cystic fibrosis.